Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
Rhea-AI Summary
Moderna (NASDAQ:MRNA) priced an upsized private offering of $2.6 billion aggregate principal amount of 0.00% Convertible Senior Notes due 2032, sold to qualified institutional buyers under Rule 144A. The deal was increased from a previously announced $2.0 billion, with initial purchasers granted a $400 million option for additional notes.
The notes are senior unsecured, carry no regular interest, and mature on March 1, 2032, unless earlier converted, redeemed or repurchased. Moderna estimates net proceeds of about $2,562.9 million (or $2,957.3 million if the option is fully exercised), and expects to use approximately $285.0 million for capped call transactions and the remainder for general corporate purposes, potentially including oncology growth investments and debt repayment.
The initial conversion rate is 4.7487 shares per $1,000 (conversion price ~$210.58), a 47.5% premium to the $142.77 share price on August 27, 2026. Capped calls with a cap price of $392.6175 (a 175.0% premium) are intended to reduce dilution and/or offset cash payments above principal upon conversion, subject to customary adjustments and conditions.
Positive
- $2.6 billion 0.00% convertible notes due 2032 priced in Rule 144A offering
- Offering upsized from $2.0 billion to $2.6 billion principal amount
- Estimated net proceeds up to $2,957.3 million including overallotment option
- Initial conversion premium of 47.5% over $142.77 share price
- Capped call cap set at $392.6175, a 175.0% premium to spot
- Portion of proceeds may support oncology business growth and debt repayment
Negative
- Convertible structure introduces potential equity dilution at conversion price of about $210.58 per share
- Company to spend approximately $285.0 million on capped call transactions
- New senior unsecured notes add to overall debt obligations despite 0.00% coupon
News Explained
The priced financing is not yet closed; completion would add senior debt, while future conversion could alter existing common ownership.
Moderna has priced
The notes can be settled in cash, common shares, or a combination at Moderna's election; issuing additional shares would increase total share count and reduce an existing holder's percentage ownership absent offsetting changes.
Measured against the last reported quarter's operating cash outflow, the gross offering equals
The specific near-term resolution points are the
Sources and calculations
- Moderna pricing announcement for convertible senior notes (2026-08-28)
- Dilution definition (2026-07-17)
- Moderna second-quarter 2026 fundamentals (2026Q2)
- Offering gross against the last reported quarterly operating outflow, in days at that rate $2,600,000,000 / ($526,000,000 / 91) = 449.8 days
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 27 | FDA approval | Positive | -4.6% | FDA approved updated 2026-2027 COVID-19 vaccine formulations for specified populations. |
| Aug 27 | Private placement | Negative | -4.6% | Company proposed convertible notes financing for qualified institutional buyers. |
| Aug 19 | Phase 3 clinical data | Positive | +177.0% | INTerpath-001 met recurrence-free and distant metastasis-free survival endpoints. |
| Aug 05 | FDA approval | Positive | -4.3% | FDA granted full approval for Moderna's mFLUSIVA seasonal influenza vaccine. |
| Aug 04 | Phase 1 clinical trial | Positive | +3.4% | Health Canada authorized trial initiation and first participant vaccinations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historically, positive clinical news aligned with gains, while FDA approvals diverged; the prior private-placement announcement aligned with a decline.
Key Terms
convertible senior notes financial
rule 144a regulatory
capped call transactions financial
fundamental change financial
qualified institutional buyers financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt
Moderna has also purchased a hedge overlay intended to offset dilution up to a cap initially equal to a
CAMBRIDGE, MA / ACCESS Newswire / August 28, 2026 / Moderna, Inc. (NASDAQ:MRNA) ("Moderna"), today announced the pricing of
The notes will be general senior unsecured obligations of Moderna. The notes will not bear regular interest and the principal amount of the notes will not accrete. The notes will mature on March 1, 2032, unless earlier converted, redeemed or repurchased.
Moderna estimates that the net proceeds from the offering will be approximately
The notes will be convertible at the option of the holders in certain circumstances. Upon conversion, Moderna will pay or deliver, as the case may be, cash, shares of Moderna's common stock or a combination of cash and shares of Moderna's common stock, at Moderna's election.
The conversion rate will initially be 4.7487 shares of Moderna's common stock per
Moderna may not redeem the notes prior to September 6, 2029, except in the event of a cleanup redemption as described below. Moderna may redeem for cash all or any portion of the notes (subject to certain limitations), at its option, on a redemption date on or after September 6, 2029 and before the 21st scheduled trading day immediately prior to the maturity date if the last reported sale price of Moderna's common stock has been at least
If Moderna undergoes a "fundamental change" (as defined in the indenture that will govern the notes) then, subject to certain conditions and exceptions, holders may require Moderna to repurchase for cash all or any portion of their notes at a fundamental change repurchase price equal to
In connection with the pricing of the notes, Moderna entered into privately negotiated capped call transactions with certain financial institutions (the "option counterparties"). The capped call transactions cover, subject to customary adjustments, the number of shares of Moderna's common stock initially underlying the notes. The capped call transactions are expected generally to reduce the potential dilution to Moderna's common stock upon any conversion of notes and/or offset any cash payments Moderna is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. If the initial purchasers exercise their option to purchase additional notes, Moderna expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions with the option counterparties.
The cap price of the capped call transactions relating to the notes will initially be
In connection with establishing their initial hedges of the capped call transactions, Moderna expects that the option counterparties or their respective affiliates will purchase shares of Moderna's common stock and/or enter into various derivative transactions with respect to Moderna's common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Moderna's common stock or the notes at that time.
In addition, Moderna expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Moderna's common stock and/or purchasing or selling Moderna's common stock or other securities of Moderna in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so following any early conversion, repurchase or redemption of the notes, to the extent Moderna unwinds a corresponding portion of the capped call transactions or if Moderna otherwise unwinds all or a portion of the capped call transactions, and during the final observation period for the conversion of notes). This activity could also cause or avoid an increase or a decrease in the market price of Moderna's common stock or the notes, which could affect the ability of a holder of notes to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares and value of the consideration, if any, that a holder of notes will receive upon conversion of the notes.
The notes were only offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act by means of a private offering memorandum. The offer and sale of the notes and any shares of Moderna's common stock issuable upon conversion of the notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.
This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the timing and completion of the proposed offering of the notes and capped call transactions, the anticipated use of proceeds from the offering, and the grant of the option to the initial purchasers. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire